Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture

By Halperin S.A.   Nestruck A.C.   Eastwood B.J.  

Vaccine, Vol. 16, Iss. 13, 1998-08 ,pp. : 1331-1335

Elsevier

Access to resources Recommend Favorite

Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: implications for vaccine manufacture

By Robertson J.S.   Cook P.   Attwell A.-M.   Williams S.P.  

Vaccine, Vol. 13, Iss. 16, 1995-11 ,pp. : 1583-1588

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children

By Halperin S.A.   Smith B.   Mabrouk T.   Germain M.   Trepanier P.   Hassell T.   Treanor J.   Gauthier R.   Mills E.L.  

Vaccine, Vol. 20, Iss. 7, 2002-01 ,pp. : 1240-1247

Elsevier

Access to resources Recommend Favorite

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

By Kistner O.   Barrett P.N.   Mundt W.   Reiter M.   Schober-Bendixen S.   Dorner F.  

Vaccine, Vol. 16, Iss. 9, 1998-05 ,pp. : 960-968

Elsevier

Access to resources Recommend Favorite

Human diploid cell culture rabies vaccine (HDCV) and purified chick embryo cell culture rabies vaccine (PCECV) both confer protective immunity against infection with the silver-haired bat rabies virus strain (SHBRV)

By Dietzschold B.   Hooper D.C.  

Vaccine, Vol. 16, Iss. 17, 1998-10 ,pp. : 1656-1659

Elsevier

Access to resources Recommend Favorite